Health

Pediatrics study links nirsevimab to fewer hospitalizations in the second winter

A study in Pediatrics associates nirsevimab with 17% fewer respiratory hospitalizations in the second RSV season. What it means for clinics in Mexico.

Vial de nirsevimab junto a incubadora neonatal en una clínica pediátrica

An observational study of 1,375 infants in Andalusia, published in the journal Pediatrics in August 2026 and reported on November 16, 2026, associates the monoclonal antibody nirsevimab with 17% fewer hospitalizations for lower respiratory tract infections in the baby's second respiratory syncytial virus (RSV) season.

The estimated absolute reduction was 17.0%, with a 95% confidence interval of 3.2% to 30.8%; it rose to 25.4% among cases with confirmed RSV and to 27.7% in minors with a history of inhaler use, according to Infobae, which reported the study with information from the EFE agency. The figures correspond to the 2024-2025 season, the second after the dose.

The work was designed as a community-based case-control study in nine Andalusian pediatric hospitals, with minors born between April 1, 2023 and March 31, 2024: 275 hospitalized in the 2024-2025 season and 1,100 controls matched by date of birth and province, according to the study record on PubMed. The protection documented in the first season is around 80%, according to the Andalusian Health Service. The point matters in Mexico because the winter campaign that began on October 12, 2026 and runs through March 31, 2027 addresses RSV with maternal vaccination between weeks 32 and 36 of gestation, not with the antibody given to the baby, according to MVS Noticias.

The authors are researchers from the Multidisciplinary Pediatric Research Group of IBIMA, the Regional University Hospital of Málaga and the University of Málaga, with David Moreno Pérez as first author. The analysis applied statistical models to reduce the effect of possible confounding factors. Cofepris authorized nirsevimab in June 2025 and in December of that year it was sold only in the private sector, at close to 10,000 pesos per dose, El Norte reported. The authors themselves describe the finding as an association, not causation, and argue that it opens the door to cost-effectiveness evaluations with a two-season horizon.

For a pediatric clinic or a payer, the data leaves two questions: whether their cost-effectiveness model counts one season or two, and how the price per dose is divided between hospitalizations avoided in the first winter and in the second.

This article was drafted with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.

Sources